{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023974","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.107711+00:00","generated_at":"2026-06-11T09:06:33.367005+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Windtree shareholders approve 2020 equity plan amendment adding 645,000 shares","bullets":["Amendment to 2020 Plan increases authorized shares by 645,000 to 738,175 total shares.","Evergreen provision removed; share recycling prohibited; one-year minimum vesting imposed; dividends on unvested awards banned.","All five director nominees elected: Craig E. Fraser, Daniel Geffken, Robert Scott, Mark Strobeck, Leslie J. Williams.","Advisory vote on executive compensation passed: 666,480 for, 86,688 against, 9,587 abstentions (87.4% of votes cast).","Ratification of EisnerAmper LLP as independent auditor for 2023 approved: 2,120,083 for, 48,301 against, 74,426 abstentions."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023974","json":"https://secwatch.observer/filing/0001437749-23-023974.json","markdown":"https://secwatch.observer/filing/0001437749-23-023974.md","text":"https://secwatch.observer/filing/0001437749-23-023974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774923023974/0001437749-23-023974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774923023974/wint20230816_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:06:33.367005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12018113aa5652adfc0d2f7927830514b57907fe","claim":"WINDTREE THERAPEUTICS INC /DE/ shareholders approved Ratification of Appointment of EisnerAmper LLP as the Company's Independent Registered Public Accounting Firm for 2023 at the 2023-08-15 meeting.","evidence_excerpt":"The votes with respect to the ratification of appointment of EisnerAmper LLP as the Company's Independent Registered Public Accounting Firm for 2023 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 2,120,083 48,301 74,426 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923023974/0001437749-23-023974-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-15"}],"fact_type":"shareholder_vote"},{"claim_id":"a9fa922cf56f39cacce286c82491193605158de4","claim":"WINDTREE THERAPEUTICS INC /DE/ shareholders approved Election of the Five Director Nominees to Serve until the Company's 2024 Annual Meeting at the 2023-08-15 meeting.","evidence_excerpt":"The votes with respect to the election of five directors to hold office until the 2024 annual meeting were as follows: Director Votes For Votes Withheld Broker Non-Votes Craig E. Fraser 740,143 22,612 1,480,055 Daniel Geffken 728,246 34,509 1,480,055 Robert Scott, M.D. 591,638 171,117 1,480,055 Mark Strobeck, Ph.D. 729,893 32,862 1,480,055 Leslie J. Williams 567,849 194,906 1,480,055","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923023974/0001437749-23-023974-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-15"}],"fact_type":"shareholder_vote"},{"claim_id":"c9c060171b8069b6ebbe980938ff6109f3201dcc","claim":"WINDTREE THERAPEUTICS INC /DE/ shareholders approved Approval of the Amended and Restated Windtree Therapeutics 2020 Equity Incentive Plan at the 2023-08-15 meeting.","evidence_excerpt":"The votes with respect to the approval of the Amended and Restated Windtree Therapeutics 2020 Equity Incentive Plan were as follows: Votes For Votes Against Abstentions Broker Non-Votes 669,259 88,539 4,957 1,480,055","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923023974/0001437749-23-023974-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-15"}],"fact_type":"shareholder_vote"},{"claim_id":"e4c5a0996a73ccb46243ca87ebe50bb7bab34c4a","claim":"WINDTREE THERAPEUTICS INC /DE/ shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2023-08-15 meeting.","evidence_excerpt":"The votes with respect to the approval, on an advisory basis, of the compensation of the Company's named executive officers were as follows: Votes For Votes Against Abstentions Broker Non-Votes 666,480 86,688 9,587 1,480,055","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923023974/0001437749-23-023974-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}